(Q50561584)
Statements
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 (English)
J Overgaard
H S Hansen
M Overgaard
A Berthelsen
B Lindeløv
1 February 1998